Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor?) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors

详细信息    查看全文

• 作者：G. Donders ; G. Bellen ; P. Neven ; P. Grob…
• 刊名：European Journal of Clinical Microbiology & Infectious Diseases
• 出版年：2015
• 出版时间：October 2015
• 年：2015
• 卷：34
• 期：10
• 页码：2023-2028
• 全文大小：1,109 KB
• 参考文献：1.McGroarty JA (1993) Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol 6:251-64CrossRef PubMed
  2.Redondo-Lopez V, Cook RL, Sobel JD (1990) Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 12(5):856-72CrossRef PubMed
  3.Witkin SS, Linhares IM, Giraldo P (2007) Bacterial flora of the female genital tract: function and immune regulation. Best Pract Res Clin Obstet Gynaecol 21(3):347-54CrossRef PubMed
  4.Witkin SS, Linhares IM, Giraldo P, Ledger WJ (2007) An altered immunity hypothesis for the development of symptomatic bacterial vaginosis. Clin Infect Dis 44(4):554-57CrossRef PubMed
  5.Donders G, Neven P, Moegele M, Lintermans A, Bellen G, Prasauskas V et al (2014) Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 145(2):371-79CrossRef PubMed Central PubMed
  6.Bottiglione F, Volpe A, Esposito G, Aloysio DD (1995) Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. Maturitas 22(3):227-32CrossRef PubMed
  7.Bachmann GA, Nevadunsky NS (2000) Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 61(10):3090-096PubMed
  8.Nappi RE, Polatti F (2009) The use of estrogen therapy in women's sexual functioning (CME). J Sex Med 6(3):603-16CrossRef PubMed
  9.Nappi RE, Kokot-Kierepa M (2010) Women's voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 67(3):233-38CrossRef PubMed
  10.Sturdee DW, Panay N (2010) Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 13(6):509-22CrossRef PubMed
  11.de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD et al (2013) Global Consensus Statement on menopausal hormone therapy. Maturitas 74(4):391-92CrossRef PubMed
  12.Heimer GM, Englund DE (1986) Plasma oestriol following vaginal administration: morning versus evening insertion and influence of food. Maturitas 8:239-43CrossRef PubMed
  13.Kaiser RR, Michael-Hepp J, Weber W, Graf F, Lauritzen C (2000) Absorption of estriol from vaginal tablets after single and repeated application in healthy, postmenopausal women. Therapiewoche 3:2-
  14.Lauritzen C, Graf F, Mucha M (1984) Restoration of the physiological vaginal environment with Doederlein bacteria and estriol. Frauenarzt 4:5-
  15.Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G (2005) The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 112(2):234-40CrossRef PubMed
  16.Unlu C, Donders G (2011) Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review. J Turkish-German Gynecol Assoc 12:239-46CrossRef
  17.Jaisamrarn U, Triratanachat S, Chaikittisilpa S, Grob P, Prasauskas V, Taechakraichana N (2013) Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy: a double-blind randomized trial followed by open-label maintenance therapy. Climacteric 16(3):347-55CrossRef PubMed Central PubMed
  18.Donders GG, Marconi C, Bellen G, Donders F, Michiels T (2015) Effect of short training on vaginal fluid microscopy (wet mount) learning. J Low Genit Tract Dis 19:165-69CrossRef PubMed
  19.Donders G (2010) Diagnosis and management of bacterial vaginosis and other types of abnormal vaginal bacterial flora: a review. Obstet Gynecol Surv 65(7):462-73
  20.Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B (2002) Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG 109(1):34-3CrossRef PubMed
  21.Buhling KJ, Eydeler U, Borregaard S, Schlegelmilch R, Suesskind M (2012) Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. Arzneimittelforschung 62(8):378-83CrossRef PubMed
  22.Cano A, Estevez J, Usandizaga R, Gallo JL, Guinot M, Delgado JL et al (2012) The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a pivotal phase III study. Menopause 19(10):1130-139CrossRef PubMed
  23.Biglia N, Peano E, Sgandurra P, Moggio G, Panuccio E, Migliardi M et al (2010) Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study. Gynecol Endocrinol 26(6):404-12
  24.Capobianco G, Wenger JM, Meloni GB, Dessole M, Cherchi PL, Dessole S (2013) Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenita
• 作者单位：G. Donders (1) (2)
  G. Bellen (2)
  P. Neven (3)
  P. Grob (5)
  V. Prasauskas (5)
  S. Buchholz (4)
  O. Ortmann (4)
  
  1. Department of Obstetrics and Gynecology, University Antwerp, Antwerp, Belgium
  2. Femicare vzw, Clinical Research for Women, Gasthuismolenstraat 31, 3300, Tienen, Belgium
  3. Department of Obstetrics and Gynecology, Gasthuisberg Hospital, University Leuven, Leuven, Belgium
  5. Medinova AG, Zurich, Switzerland
  4. Department of Obstetrics and Gynecology, University Medical Center Regensburg, Regensburg, Germany
  
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Biomedicine
  Medical Microbiology
  Internal Medicine
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1435-4373

文摘

This study was a detailed microscopic analysis of the changes of vaginal microflora characteristics after application of 0.03 mg estriol-lactobacilli combination on the vaginal ecosystem in postmenopausal breast cancer (BC) survivors on aromatase inhibitors (AI) with severe atrophic vaginitis. A total of 16 BC women on AI applied daily one vaginal tablet of Gynoflor? for 28 days followed by a maintenance therapy of three tablets weekly for 8 weeks. During four follow up visits a smear from the upper lateral vaginal wall was analysed by phase contrast microscopy at 400 times magnification in order to classify the lactobacillary grades(LBG), bacterial vaginosis (BV), aerobic vaginitis (AV), vulvovaginal candidosis (VVC), proportional number of leukocytes and evidence of parabasal cells and epitheliolysis. LBG improved from 81 % LBG-III at entry to 88 % LBG-I&IIa after 2 weeks of initial therapy, which further improved upon follow up (p-lt;-.001). Whereas BV was a rare event, AV was frequent and substantially improved during treatment (p-lt;-.01). While at entry most patients had moderate or severe AV, after maintenance therapy no patient except one had AV. The number of leukocytes dropped dramatically from a score of 1.78?±-.70 to 1.06?±-.25 which was consistent till the end of the study (p-lt;-.01). Parabasal cells dropped from a score of 3.4?±-.64 at entry to 1.3?±-.60 at the final visit (p _trend-lt;-.01). Starting from a low rate of Candida colonisation of 2/14 (14 %), a sudden rise to 7/16 (44 %) occurred after 2 weeks, to return back to base levels at susequent visits. The vaginal use of ultra-low dose estriol and lactobacilli results in rapid and enduring improvement of all markers of the vaginal microflora and epithelial vaginal cell quality in women with breast cancer on AI with dyspareunia. Candida may develop soon after its use, but rapidly disappears again upon their prolonged use. Due to its excellent safety profiles and clinical efficacy we recommend this product as first choice in women on AI with severe dyspareunia.